Effects of harmine on dopamine output and metabolism in rat striatum: role of monoamine oxidase-A inhibition. 2001

M Iurlo, and G Leone, and B Schilström, and L Linnér, and G Nomikos, and P Hertel, and B Silvestrini, and H Svensson
Department of Physiology and Pharmacology, Division of Pharmacology, Karolinska Institutet, Stockholm, Sweden.

In vivo microdialysis was used to investigate the effects of acute injections of harmine on extracellular concentrations of dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), and 5-hydroxindoleacetic acid (5-HIAA) in the striatum of awake rats. Administration of harmine in doses of 0.5, 2.5, and 10 mg/kg (i.p.) elicited a dose-dependent increase of the dopamine efflux to 152, 173, and 243% and a decrease in DOPAC to 52, 36, and 10%, and HVA to 67, 45, and 20% throughout, respectively; 5-HIAA concentrations were decreased to 81, 74, and 72% only. In contrast to D-amphetamine, which also increases dopamine release and decreases its metabolites, the stimulatory action of harmine on dopamine release in the striatum was totally abolished in the presence of tetrodotoxin (1 microM). Similar to monoamine oxidase (MAO)-A inhibitors, harmine potentiated the stimulatory effect of D-amphetamine (10 microM), infused by reverse microdialysis in the striatum, on dopamine release. Pre-treatment with the benzodiazepine receptor antagonist flumazenil (5 mg/kg, i.p.) did not modulate the effect of harmine on striatal dopamine release and metabolism. Administration of the reversible MAO-A inhibitor, moclobemide (20 mg/kg, i.p.), induced an increase in dopamine to 256% and a decrease in DOPAC, HVA, and 5-HIAA to 30, 24, and 62%, respectively, reproducing a pattern similar to that of harmine. Taken together, these results indicate that harmine affects the brain dopamine system probably by acting as a MAO-A inhibitor and not as an inverse agonist for the benzodiazepine receptors.

UI MeSH Term Description Entries
D008297 Male Males
D008995 Monoamine Oxidase An enzyme that catalyzes the oxidative deamination of naturally occurring monoamines. It is a flavin-containing enzyme that is localized in mitochondrial membranes, whether in nerve terminals, the liver, or other organs. Monoamine oxidase is important in regulating the metabolic degradation of catecholamines and serotonin in neural or target tissues. Hepatic monoamine oxidase has a crucial defensive role in inactivating circulating monoamines or those, such as tyramine, that originate in the gut and are absorbed into the portal circulation. (From Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 8th ed, p415) EC 1.4.3.4. Amine Oxidase (Flavin-Containing),MAO,MAO-A,MAO-B,Monoamine Oxidase A,Monoamine Oxidase B,Type A Monoamine Oxidase,Type B Monoamine Oxidase,Tyramine Oxidase,MAO A,MAO B,Oxidase, Monoamine,Oxidase, Tyramine
D008996 Monoamine Oxidase Inhibitors A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414) MAO Inhibitor,MAO Inhibitors,Reversible Inhibitors of Monoamine Oxidase,Monoamine Oxidase Inhibitor,RIMA (Reversible Inhibitor of Monoamine Oxidase A),Reversible Inhibitor of Monoamine Oxidase,Inhibitor, MAO,Inhibitor, Monoamine Oxidase,Inhibitors, MAO,Inhibitors, Monoamine Oxidase
D003342 Corpus Striatum Striped GRAY MATTER and WHITE MATTER consisting of the NEOSTRIATUM and paleostriatum (GLOBUS PALLIDUS). It is located in front of and lateral to the THALAMUS in each cerebral hemisphere. The gray substance is made up of the CAUDATE NUCLEUS and the lentiform nucleus (the latter consisting of the GLOBUS PALLIDUS and PUTAMEN). The WHITE MATTER is the INTERNAL CAPSULE. Lenticular Nucleus,Lentiform Nucleus,Lentiform Nuclei,Nucleus Lentiformis,Lentiformis, Nucleus,Nuclei, Lentiform,Nucleus, Lenticular,Nucleus, Lentiform,Striatum, Corpus
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006247 Harmine Alkaloid isolated from seeds of PEGANUM HARMALA; ZYGOPHYLLACEAE. It is identical to banisterine, or telepathine, from Banisteria caapi and is one of the active ingredients of hallucinogenic drinks made in the western Amazon region from related plants. It has no therapeutic use, but (as banisterine) was hailed as a cure for postencephalitic PARKINSON DISEASE in the 1920's. 9H-Pyrido(3,4-b)indole, 7-methoxy-1-methyl-,Banisterine,Leucoharmine,Telepathine,Yageine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015314 Dialysis Solutions Solutions prepared for exchange across a semipermeable membrane of solutes below a molecular size determined by the cutoff threshold of the membrane material. Dialysate,Dialysis Solution,Dialyzate,Dialysates,Dialyzates,Solution, Dialysis,Solutions, Dialysis
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats

Related Publications

M Iurlo, and G Leone, and B Schilström, and L Linnér, and G Nomikos, and P Hertel, and B Silvestrini, and H Svensson
March 1994, European journal of pharmacology,
M Iurlo, and G Leone, and B Schilström, and L Linnér, and G Nomikos, and P Hertel, and B Silvestrini, and H Svensson
September 1990, Journal of neurochemistry,
M Iurlo, and G Leone, and B Schilström, and L Linnér, and G Nomikos, and P Hertel, and B Silvestrini, and H Svensson
August 1981, Journal of neurochemistry,
M Iurlo, and G Leone, and B Schilström, and L Linnér, and G Nomikos, and P Hertel, and B Silvestrini, and H Svensson
January 1973, Journal of neural transmission,
M Iurlo, and G Leone, and B Schilström, and L Linnér, and G Nomikos, and P Hertel, and B Silvestrini, and H Svensson
January 1970, Biochemical pharmacology,
M Iurlo, and G Leone, and B Schilström, and L Linnér, and G Nomikos, and P Hertel, and B Silvestrini, and H Svensson
January 1980, Cellular and molecular biology, including cyto-enzymology,
M Iurlo, and G Leone, and B Schilström, and L Linnér, and G Nomikos, and P Hertel, and B Silvestrini, and H Svensson
August 1974, Japanese journal of pharmacology,
M Iurlo, and G Leone, and B Schilström, and L Linnér, and G Nomikos, and P Hertel, and B Silvestrini, and H Svensson
July 1963, Annals of the New York Academy of Sciences,
M Iurlo, and G Leone, and B Schilström, and L Linnér, and G Nomikos, and P Hertel, and B Silvestrini, and H Svensson
November 1994, Brain research,
M Iurlo, and G Leone, and B Schilström, and L Linnér, and G Nomikos, and P Hertel, and B Silvestrini, and H Svensson
May 1972, European journal of pharmacology,
Copied contents to your clipboard!